Seattle Genetics, Inc. (SGEN): Price and Financial Metrics
SGEN Stock Summary
- For SGEN, its debt to operating expenses ratio is greater than that reported by merely 7.73% of US equities we're observing.
- In terms of twelve month growth in earnings before interest and taxes, Seagen Inc is reporting a growth rate of -488.09%; that's higher than merely 3.53% of US stocks.
- Revenue growth over the past 12 months for Seagen Inc comes in at 137.32%, a number that bests 95.71% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Seagen Inc, a group of peers worth examining would be CDNS, SNPS, QRVO, EXEL, and WDC.
- SGEN's SEC filings can be seen here. And to visit Seagen Inc's official web site, go to www.seattlegenetics.com.
SGEN Stock Price Chart Interactive Chart >
SGEN Price/Volume Stats
|Current price||$149.35||52-week high||$213.94|
|Prev. close||$145.45||52-week low||$90.57|
|Day high||$150.27||Avg. volume||1,237,291|
|50-day MA||$170.37||Dividend yield||N/A|
|200-day MA||$172.20||Market Cap||27.06B|
Seattle Genetics, Inc. (SGEN) Company Bio
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. The company was founded in 1998 and is based in Bothell, Washington.
SGEN Latest News Stream
|Loading, please wait...|
SGEN Latest Social Stream
View Full SGEN Social Stream
Latest SGEN News From Around the Web
Below are the latest news stories about Seagen Inc that investors may wish to consider to help them evaluate SGEN as an investment opportunity.
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that it has been notified of an unsolicited “mini-tender” offer dated February 22, 2021, made by TRC Capital Investment Corporation, an Ontario, Canada corporation, to purchase up to 1,000,000 shares of Seagen's common stock. According to TRC, its “mini-tender” offer price of $151.00 per share was approximately 4.28% below the closing price of Seagen's common stock on February 19, 2021, the last trading day prior to the
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 2:40 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seagen’s website at www.seagen.com in the Investors section. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a mea
Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV® (enfortumab vedotin-ejfv). One submission, based on the phase 3 EV-301 trial, seeks to convert PADCEV’s accelerated approval to regular approval. The second submission, based on th
It's been a soft week for Seagen Inc. ( NASDAQ:SGEN ) shares, which are down 13%. But that does not change the realty...
The following slide deck was published by Seagen Inc. in conjunction with their 2020 Q4 earnings call....
SGEN Price Returns
Continue Researching SGENWant to do more research on Seattle Genetics Inc's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!